EViv
ACLF is a life threatening medical need that is not being adequaly adressed.
:quality(80)/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2023/12/foie-1.png)
EViv is being developed in Acute Chronic Liver Failure (ACLF), a clinical syndrome of sudden hepatic decompensation observed in patients with pre-existing chronic liver disease and associated with one or more extrahepatic organ failures and increased mortality.
ACLF can cause serious complications, including bleeding and increased pressure in the brain. It’s a medical emergency that requires hospitalization. Depending on the cause, acute liver failure can sometimes be reversed with treatment.
Based on the CANONIC study data, the 28-day mortality rate in ACLF-1 is 23%. Grade 2 ACLF is defined as two organ failures with a 28-day mortality rate of 32%, while grade 3 ACLF is defined by three or more organ failures and a mortality rate of >75%.
There is no approved drug : external organ assistance while treating the root cause of decompensation.
EViv proof-of-concept
EViv has demonstrated promising preclinical in vitro and in vivo data on liver injury. First-in-human studies in ACLF indication are planned for early 2028.